Arecor Therapeutics PLC Change of Nominated Advisor and Joint Broker

RNS Number : 6601S

Arecor Therapeutics PLC

09 January 2025

 

Arecor Therapeutics plc

("Arecor" or the "Group")

 

CHANGE OF NOMINATED ADVISOR AND JOINT BROKER

 

Cambridge, UK, 9 January 2025: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, today announces that Singer Capital Markets Advisory LLP has been appointed as the Company's Nominated Advisor and Joint Broker with immediate effect.

 

-ENDS-

                                                                                                                                

For more information, please contact:

 

Arecor Therapeutics plc	www.arecor.com
Dr Sarah Howell, Chief Executive Officer David Ellam, Interim Chief Financial Officer	Tel: [phone] Email: [e-mail]
Singer Capital Markets Advisory LLP (NOMAD and Joint Broker) Phil Davies, Sam Butcher	Tel : [phone]
WG Partners LLP (Joint Broker)
Nigel Barnes, Satheesh Nadarajah David Wilson, Claes Spang	Tel: [phone]
ICR Healthcare
Chris Gardner, David Daley, Lindsey Neville	Tel: [phone] Email: [e-mail]

 

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.  For further details please see our website, www.arecor.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

APPSSLESAEISEEF